ROR2 and neoplasm: A conditionally active biologic (CAB)-ROR2- antibody drug conjugate (ADC) named BA3021 was developed to selectively bind to ROR2 in the context of tumour microenvironment and has been reported to inhibit growth of ROR2 positive cell lines and xenografts of several cancers [50].